12/18
07:33 pm
cstl
Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
Neutral
Report
Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
12/17
07:00 am
cstl
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Low
Report
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
12/13
02:18 pm
cstl
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
12/12
08:06 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
12/12
07:39 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
12/12
07:00 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
12/9
07:00 am
cstl
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Low
Report
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
11/21
07:04 pm
cstl
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
Medium
Report
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
11/20
01:33 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
09:13 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
11/17
07:00 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
11/14
08:10 am
cstl
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]
Low
Report
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]
11/14
07:00 am
cstl
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Low
Report
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
11/11
07:00 am
cstl
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
11/7
03:48 am
cstl
SciBase: Interim report [Yahoo! Finance]
Low
Report
SciBase: Interim report [Yahoo! Finance]
11/7
02:37 am
cstl
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million [Yahoo! Finance]
Low
Report
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million [Yahoo! Finance]
11/7
02:27 am
cstl
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million
Low
Report
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million
11/7
12:23 am
cstl
Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why [Yahoo! Finance]
Low
Report
Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why [Yahoo! Finance]
11/4
08:12 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at BTIG Research.
11/4
07:50 pm
cstl
Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth [Yahoo! Finance]
Medium
Report
Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth [Yahoo! Finance]
11/4
12:38 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Robert W. Baird from $39.00 to $41.00. They now have an "outperform" rating on the stock.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Robert W. Baird from $39.00 to $41.00. They now have an "outperform" rating on the stock.
11/3
04:07 pm
cstl
Castle Biosciences Reports Third Quarter 2025 Results
High
Report
Castle Biosciences Reports Third Quarter 2025 Results
11/3
04:05 pm
cstl
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
High
Report
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
10/30
12:26 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
07:00 am
cstl
Castle Biosciences to Participate in Upcoming Investor Conferences
Low
Report
Castle Biosciences to Participate in Upcoming Investor Conferences